Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE: COST | $2.6B Rx revenue 2024 (11th largest US pharmacy); 19%+ prescription growth; below-market drug pricing open to non-members in most states; no PBM markup model
Costco Pharmacy operates as a pharmacy benefit integrated directly into Costco's warehouse membership model, offering prescription drug dispensing at significantly below-market prices by leveraging Costco's bulk purchasing power and low-margin retail philosophy. Founded as an extension of Costco Wholesale's membership warehouse business, the pharmacy operates on the principle that drug costs should be transparent and accessible, a differentiated stance in an industry dominated by opaque PBM pricing arrangements. Costco Pharmacy serves both Costco members and, in most states, non-members who can access the pharmacy counter without a warehouse membership.\n\nThe pharmacy operates across 650+ Costco warehouse locations in the United States, Puerto Rico, and internationally, offering a formulary of generic and brand-name prescription drugs at prices that often undercut major chains by 50–80%. Costco does not participate in most prescription drug insurance networks, which keeps overhead low and pricing simple — members pay a known cash price rather than navigating co-pay structures. The pharmacy also offers compounding services, pet medications, and immunizations at select locations, and integrates with Costco's optical and hearing aid departments to serve the full healthcare needs of its membership base.\n\nCostco Pharmacy is consistently ranked among the lowest-cost pharmacy options in independent drug pricing surveys, creating strong loyalty among members managing chronic conditions or high-cost specialty medications. The pharmacy benefits from Costco's 130 million+ cardholders globally, who view low-cost pharmacy access as one of the core value drivers of their membership. As PBM reform and drug pricing transparency become legislative priorities in the US, Costco's no-frills cash-pay model is increasingly viewed as a reference point for what pharmacy pricing could look like without intermediary markup layers.
Pittsburgh ambient clinical AI (founded by cardiologist) at $5.3B valuation Jun 2025; $800M total ($300M a16z/Khosla Series E) deployed at UPMC 12K clinicians, Mayo Clinic, Johns Hopkins competing with Nuance DAX for physician documentation.
Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led by Andreessen Horowitz and Khosla Ventures at a $5.3 billion valuation, following a $250 million Series D just four months prior at a $2.8 billion valuation — providing physicians, nurses, and care teams at 150+ health systems with AI that automatically converts patient-clinician conversations into structured clinical notes, saving physicians an average of 3 hours daily and generating high-quality documentation from UPMC (scaling to 12,000 clinicians enterprise-wide), Mayo Clinic, Johns Hopkins, and Emory Healthcare. Abridge's AI is trained on a proprietary dataset of over 1.5 million medical encounters, delivering specialty-specific documentation through deep Epic EHR integration. Founded in 2018 by cardiologist Dr. Shiv Rao.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.